BNP Paribas Financial Markets
PHAS

BNP Paribas Financial Markets’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

BNP Paribas Financial Markets’s Portfolio PHAS Stock Details PHAS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-79
Closed -$14 – 4979
2022
Q3 		$14 Hold
79
– – ﹤0.01% 4703
2022
Q2 		$47 Hold
79
– – ﹤0.01% 4037
2022
Q1 		$104 Hold
79
– – ﹤0.01% 4093
2021
Q4 		$206 Sell
79
-301
-79% -$910 ﹤0.01% 4146
2021
Q3 		$1.18K Buy
380
+79
+26% +$264 ﹤0.01% 3858
2021
Q2 		$1.12K Sell
301
-2,017
-87% -$6.71K ﹤0.01% 3933
2021
Q1 		$8.02K Sell
2,318
-921
-28% -$3.74K ﹤0.01% 3840
2020
Q4 		$10.9K Sell
3,239
-135
-4% -$483 ﹤0.01% 3920
2020
Q3 		$11.8K Buy
3,374
+2,554
+311% +$10.3K ﹤0.01% 3939
2020
Q2 		$3.77K Sell
820
-3,404
-81% -$15.1K ﹤0.01% 4101
2020
Q1 		$14K Buy
4,224
+2,334
+123% +$10.7K ﹤0.01% 3981
2019
Q4 		$11.5K Buy
1,890
+157
+9% +$647 ﹤0.01% 4112
2019
Q3 		$7.23K Buy
1,733
+1,698
+4,851% +$13.5K ﹤0.01% 4212
2019
Q2 		$459 Buy
+35
New +$429 ﹤0.01% 4413

Other funds holding PHAS

DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
HLA
Hamilton Lane Advisors Conshohocken, Pennsylvania $149M AUM 14.17% 1-Year Est. Return
IIA
IPG Investment Advisors San Diego, California $582M AUM 33.22% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

BNP Paribas Financial Markets's PHAS Position: Q4 2022 in Review

BNP Paribas Financial Markets sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q4 2022, closing a stake of 79 shares — an estimated $14 sold.

BNP Paribas Financial Markets first reported a position in PHAS in Q2 2019 and held it in 14 quarters. The position peaked at $14K in Q1 2020. 5 funds tracked by Wall St. Rank hold PHAS as of Q4 2022.

  • BNP Paribas Financial Markets reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • BNP Paribas Financial Markets sold 79 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q4 2022, an estimated $14.
  • BNP Paribas Financial Markets first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q2 2019 and held it in 14 quarters.
  • BNP Paribas Financial Markets's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $14K in Q1 2020.
  • 5 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q4 2022.

Based on BNP Paribas Financial Markets's 13F filing for Q4 2022, filed 14 Feb 2023.